RSS   Newsletter   Contact   Advertise with us
Post Online Media

Avillion appoints David Chiswell to board

Share on Twitter Share on LinkedIn
Staff Writer | London, United Kingdom |
David ChiswellAvillion, a drug development company, appoints David Chiswell OBE as a non-executive director of Bond 2 Development 2 GP, the general partner of Bond Avillion 2.
Dr. Chiswell has over 30 years' experience in the biotechnology industry having co-founded Cambridge Antibody Technology (CAT) in 1990, serving as CEO from 1996 to 2002.

Since leaving CAT in 2002, Dr. Chiswell has focused on the development of early stage biotechnology companies, having previously served as a director of Arakis, non-executive chairman of Sosei, Arrow Therapeutics, Daniolabs, Nabriva Therapeutics and Kymab Ltd.

Dr. Chiswell was CEO of Nabriva Therapeutics from 2009 to 2012 and Kymab Ltd 2015 to 2018.

He currently serves as chairman of Albireo Pharma.

Dr. Chiswell is a past chairman of the UK BioIndustry Association (BIA) and in 2006 he was awarded the Most Excellent Order of the British Empire (OBE) by Her Majesty the Queen for services to the biotechnology industry.

 LATEST MOVES FROM United Kingdom 

POST Online Media Contact